BIOMAT Database Logo BIOMAT Database Logo

Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25-35) peptide as analyzed by single alanine substitution. 1995

K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Mitsubishi Kasei Institute of Life Sciences, Tokyo.

Structure-neurotoxicity relationships of amyloid beta (25-35) peptide were studied by replacing each amino acid with Ala. In contrast to the general tendency in hydrophobicity-toxicity relationships, replacement of Asn27 yielded a more hydrophobic but less toxic analog and that of Met35 gave a less hydrophobic but more toxic one. Sedimentation profiles and CD spectra indicated that peptide aggregation via intermolecular beta-sheet formation is essential for the neurotoxicity of amyloid beta (25-35) peptide. The correlation between neurotoxicity and amyloid precursor protein accumulation suggested that the latter is one of the pathways of the neuronal death caused by amyloid beta protein.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D009498 Neurotoxins Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. Alpha-Neurotoxin,Excitatory Neurotoxin,Excitotoxins,Myotoxin,Myotoxins,Neurotoxin,Alpha-Neurotoxins,Excitatory Neurotoxins,Excitotoxin,Alpha Neurotoxin,Alpha Neurotoxins,Neurotoxin, Excitatory,Neurotoxins, Excitatory
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D004622 Embryo, Mammalian The entity of a developing mammal (MAMMALS), generally from the cleavage of a ZYGOTE to the end of embryonic differentiation of basic structures. For the human embryo, this represents the first two months of intrauterine development preceding the stages of the FETUS. Embryonic Structures, Mammalian,Mammalian Embryo,Mammalian Embryo Structures,Mammalian Embryonic Structures,Embryo Structure, Mammalian,Embryo Structures, Mammalian,Embryonic Structure, Mammalian,Embryos, Mammalian,Mammalian Embryo Structure,Mammalian Embryonic Structure,Mammalian Embryos,Structure, Mammalian Embryo,Structure, Mammalian Embryonic,Structures, Mammalian Embryo,Structures, Mammalian Embryonic
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine

Related Publications

K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Activation of LA-N-2 cell phospholipases by single alanine substitution analogs of amyloid beta peptide (25-35).
March 1997, FEBS letters,
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Induction of amyloid precursor protein by the neurotoxic peptide, amyloid-beta 25-35, causes retinal ganglion cell death.
June 2010, Journal of neurochemistry,
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
[Neurotoxicity of beta-amyloid peptide 31-35 and 25-35 to cultured rat cortical neurons].
December 2009, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Protective effects of melatonin on cortico-hippocampal neurotoxicity induced by amyloid beta-peptide 25-35.
January 2002, Acta pharmacologica Sinica,
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Solution structure of amyloid beta-peptide (25-35) in different media.
August 2004, Journal of medicinal chemistry,
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Processing of amyloid precursor protein and amyloid peptide neurotoxicity.
April 2008, Current Alzheimer research,
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Neuroprotection by D-securinine against neurotoxicity induced by beta-amyloid (25-35).
October 2004, Neurological research,
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35.
May 1993, Neuroreport,
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Potentiation of beta-folding of beta-amyloid peptide 25-35 by aluminum salts.
May 1999, Neuroscience letters,
K Sato, and A Wakamiya, and T Maeda, and K Noguchi, and A Takashima, and K Imahori
Conformations and biological activities of amyloid beta peptide 25-35.
February 2010, Current protein & peptide science,
Copied contents to your clipboard!